Safe administration of sotrovimab to a COVID-19 patient with acute phase type 1 diabetes mellitus

DOI Web Site 参考文献19件
  • Tanaka Haruna
    Department of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Matsumoto Masaaki
    Department of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Hong Sung Won
    Department of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Mitsuboshi Akari
    Department of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Nagai Masashi
    Department of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Yoshino Go
    Division of Infectious Disease, Department of Pediatrics, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Otake Shogo
    Division of Infectious Disease, Department of Pediatrics, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Matsuo Susumu
    Department of Pediatrics, Toyooka Hospital, Hyogo, Japan
  • Yamada Hiroyuki
    Department of Pediatrics, Toyooka Hospital, Hyogo, Japan
  • Kurosawa Hiroshi
    Division of Pediatric Critical Care Medicine, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Kasai Masashi
    Division of Infectious Disease, Department of Pediatrics, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan
  • Ozaki Kayo
    Department of Endocrinology and Metabolism, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan

抄録

<p>Type 1 diabetes mellitus (T1DM) and poor glycemic control are risk factors for severe coronavirus disease 2019 (COVID-19). Sotrovimab can treat mild-to-moderate COVID-19 in patients at a high risk of progression to severe COVID-19. However, its safety and efficacy in T1DM patients remain to be elucidated. We report the case of a 12-yr-old patient who was treated with sotrovimab for COVID-19 immediately after treatment for diabetic ketoacidosis (DKA) due to new-onset T1DM. He presented with nausea and sore throat and was diagnosed with severe DKA and COVID-19. A productive cough and sputum developed after admission. On the 3rd day of admission, the DKA resolved, and sotrovimab was administered to prevent exacerbation of COVID-19. Although the blood glucose levels increased after the administration of sotrobimab, there was no recurrence of DKA. Hyperglycemia may be a sotrovimab-related adverse event in T1DM patients. Nevertheless, the benefits of sotrovimab treatment may far outweigh the potential risks. Thus, sotrovimab was considered safe for patients with T1DM immediately after treatment of severe DKA.</p>

収録刊行物

参考文献 (19)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ